# NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

> **NCT06494540** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 600 (estimated)

## Conditions studied

- Non-squamous Metastatic Non-Small-Cell Lung Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06494540
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-28
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06494540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06494540, "NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06494540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*